Age: 23.0
Sex: F
Vaccine: HPV4
Symptoms: Autoimmune disorder, Blood follicle stimulating hormone abnormal, Hot flush, Premature menopause
Clinical narrative: Autoimmune Disorder/autoimmune disease; other serious injuries/a constellation of adverse symptoms, complications, injuries, and other adverse events, many of which are; premature ovarian failure, likely autoimmune/hot flashes/postmenopausal range of the follicle stimulating hormone; Information has been received from a lawyer regarding a case in litigation and refers to an approximately 23-years-old adult female patient. No information was provided regarding medical history, concurrent conditions, or concomitant medications. On 04-JUN-2010, the patient was 23 years old when she received her first dosage of Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) (strength, dose, route, lot#, and expiration date were not reported). Prior to receiving her Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) injections, the patient had no autoimmune diseases. On 04-JUN-2010, the patient's health care provider recommended that the patient receive the first Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) vaccine, which was touted as a safe and effective vaccine for preventing cervical cancer. In light of the doctor's recommendations, as well as the company's relentless marketing and advertising messages, to which the patient had been exposed concerning the safety and efficacy of Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL), the patient consented to being injected with Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL). On 06-AUG-2010, the patient returned to her health care provider with complaints of hot flashes that began about two weeks prior. During the visit, the patient had a hormonal workup test performed which showed a postmenopausal range of the follicle stimulating hormone. On 17-MAR-2012, the patient was diagnosed with premature ovarian failure, likely autoimmune. Based upon her chronic and severe post-Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) symptoms, the patient had been diagnosed with premature ovarian failure. The patient contended that her Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) injections caused her to develop serious and debilitating injuries, including but not limited to autoimmune disease, as well as a constellation of adverse symptoms, complications, injuries, and other adverse events, many of which are alleged herein and all of which were caused by Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) or otherwise linked to her Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) induced autoimmune disorder. As a proximate result of the company's wrongful acts and omissions and its negligent and fraudulent testing, labeling, manufacturing, and promotion of Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL), the patient had suffered and continued to suffer severe and permanent physical injuries, including, but not limited to, her autoimmune disease and associated symptomology and has suffered severe and permanent emotional injuries, including pain and suffering. The patient also had a substantial fear of suffering additional and ongoing harms, including but not limited to now being at an increased risk of cancer, and future symptoms and harms associated with her autoimmune disease and other injuries caused by Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL). As a direct and proximate result of her Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL)-induced injuries, the patient had suffered and continues to suffer economic losses, including considerable financial expenses for medical care and treatment, and diminished income capacity and she will continue to incur these losses and expenses in the future. Outcome of the events was not recovered. Causality was considered to be related. All the events were considered to disability.  Upon internal review, autoimmune disease was considered to be medically significant.